Curaleaf Holdings, Inc. Price & Performance (CURLF)

Curaleaf International has launched its branded medical cannabis products in Australia, marking a significant step in its global growth strategy. The move targets one of the fastest-growing cannabis markets, with plans for further product innovation and partnerships to strengthen its international footprint and support local patient access.12

Curaleaf reported Q1 2025 net revenue of $310 million, down 9% year-over-year, but improved its gross margin to 50%. Adjusted EBITDA reached $65 million. Despite international growth—particularly in Germany and the UK—domestic sales faced headwinds from price compression, contributing to a net loss of $55 million for the quarter.34

Curaleaf’s short interest declined by 8% in April, with only 0.8% of its float now sold short. The short interest ratio stands at 3.9 days, suggesting relatively low bearish sentiment compared to industry peers. This shift indicates some investors may see stabilization or opportunity in the company’s current valuation.56